NO934266L - Schizofreni - Google Patents

Schizofreni

Info

Publication number
NO934266L
NO934266L NO934266A NO934266A NO934266L NO 934266 L NO934266 L NO 934266L NO 934266 A NO934266 A NO 934266A NO 934266 A NO934266 A NO 934266A NO 934266 L NO934266 L NO 934266L
Authority
NO
Norway
Prior art keywords
schizophrenia
efas
treated
combination
cell membrane
Prior art date
Application number
NO934266A
Other languages
English (en)
Other versions
NO934266D0 (no
Inventor
David Frederick Horrobin
Original Assignee
Scotia Holdings Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc
Publication of NO934266D0 publication Critical patent/NO934266D0/no
Publication of NO934266L publication Critical patent/NO934266L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

De negative symptomer ved schizofreni og/eller lave cellemembran-nivåer av EFA'er kan behandles med en kombinasjon av arachidonsyre og dokosaheksaensyre.
NO934266A 1992-11-26 1993-11-25 Schizofreni NO934266L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929224809A GB9224809D0 (en) 1992-11-26 1992-11-26 Schizophrenia

Publications (2)

Publication Number Publication Date
NO934266D0 NO934266D0 (no) 1993-11-25
NO934266L true NO934266L (no) 1994-05-27

Family

ID=10725730

Family Applications (1)

Application Number Title Priority Date Filing Date
NO934266A NO934266L (no) 1992-11-26 1993-11-25 Schizofreni

Country Status (19)

Country Link
US (1) US5516800A (no)
EP (2) EP0599576B1 (no)
JP (1) JPH06199663A (no)
CN (1) CN1104494A (no)
AT (1) ATE144706T1 (no)
AU (2) AU666782B2 (no)
CA (1) CA2109777A1 (no)
DE (1) DE69305723T2 (no)
DK (1) DK0599576T3 (no)
ES (1) ES2093935T3 (no)
GB (1) GB9224809D0 (no)
GR (1) GR3021692T3 (no)
HK (1) HK114297A (no)
MY (1) MY109905A (no)
NO (1) NO934266L (no)
NZ (1) NZ250265A (no)
RU (1) RU2123844C1 (no)
SG (1) SG47838A1 (no)
ZA (1) ZA938835B (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
EP0707487B1 (en) * 1993-06-09 2004-04-14 Martek Biosciences Corporation Methods and pharmaceutical compositions useful for treating neurological disorders
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
GB9510636D0 (en) * 1995-05-25 1995-07-19 Scotia Holdings Plc Fatty acid treatment
EP0831805A1 (en) * 1995-06-07 1998-04-01 Martek Biosciences Corporation Methods for controlling highly unsaturated fatty acid content in various tissues
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
JP4172726B2 (ja) * 1996-05-22 2008-10-29 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド シス―ドコサヘキサエン酸とドセタキセルとの共有複合体を含有する製剤
JP4151853B2 (ja) 1996-10-11 2008-09-17 スカリスタ リミテッド エイコサペンタエン酸および／またはステアリドン酸を含む治療用薬剤
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US6225444B1 (en) 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
DK1121115T4 (da) * 1998-10-15 2011-01-10 Dsm Ip Assets Bv PUFA-tilskud
GB9826899D0 (en) * 1998-12-08 1999-01-27 Knoll Ag Methods to treat depression and other psychiatric disorders and assays for compounds
CA2351469A1 (en) * 1998-12-15 2000-06-22 Susan Marie Kaup Method and composition for the maintenance and restitution of gut integrity
GB9901808D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Drugs for treatment of psychiatric and brain disorders
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
GB9923738D0 (en) 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
GB0016045D0 (en) * 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
US8552054B2 (en) 2001-03-23 2013-10-08 Luitpold Pharmaceuticals, Inc. Fatty amine drug conjugates
JP4634694B2 (ja) * 2001-03-23 2011-02-16 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド 脂肪アルコール薬物複合体
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
GB0221480D0 (en) * 2002-09-16 2002-10-23 Laxdale Ltd Treatment of anorexia nervosa (AN) and bulimia
EP1713463A4 (en) * 2004-01-19 2009-03-18 Martek Biosciences Corp REELIN DYSFUNCTION OR DICTION AND ASSOCIATED TECHNIQUES
ITMI20040069A1 (it) * 2004-01-21 2004-04-21 Tiberio Bruzzese Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
ITMI20051560A1 (it) * 2005-08-10 2007-02-11 Tiberio Bruzzese Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
EP1772146A1 (en) * 2005-10-03 2007-04-11 Neuropharma, S.A. Polyunsaturated fatty acids as bace inhibitors
WO2007050318A2 (en) * 2005-10-24 2007-05-03 Duke University Lipidomics approaches for central nervous system disorders
US8137977B2 (en) * 2006-04-24 2012-03-20 Children's Hospital & Research Center At Oakland Lipidomic approaches to determining drug response phenotypes in cardiovascular disease
WO2008081989A1 (ja) 2006-12-28 2008-07-10 Suntory Holdings Limited 神経再生剤
WO2009058799A1 (en) * 2007-11-01 2009-05-07 Wake Forest University School Of Medicine Compositions and methods for prevention and treatment of mammalian diseases
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
GB2460056A (en) * 2008-05-14 2009-11-18 Arab Science & Technology Foun Compositions comprising omega-6 fatty acids for use in treating schistosomiasis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882352A (en) * 1986-07-28 1989-11-21 Nelson Research & Development Co. Method for treating schizophrenia
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
US4588721A (en) * 1983-09-12 1986-05-13 The Upjohn Company Treatment of negative symptoms of schizophrenia
US4526902A (en) * 1983-10-24 1985-07-02 Century Laboratories, Inc. Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
GB8603621D0 (en) * 1986-02-14 1986-03-19 Habib N Modifying lipid structure of cell membranes
US5198468A (en) * 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
GB8714772D0 (en) * 1987-06-24 1987-07-29 Efamol Ltd Essential fatty acid compositions
GB8715914D0 (en) * 1987-07-07 1987-08-12 Efamol Ltd Treatment of cerabral disorders
FR2619712B1 (fr) * 1987-08-25 1990-08-31 Rhone Poulenc Sante Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la schizophrenie
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
HU208484B (en) * 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
DE3920679A1 (de) * 1989-06-23 1991-01-10 Milupa Ag Fettmischung zur herstellung von nahrungen, insbesondere saeuglingsnahrungen
DE4017979A1 (de) * 1990-06-05 1991-12-12 Meyer Lucas Gmbh & Co Lipid- bzw. phospholipid-zusammensetzungen sowie diese enthaltendes mittel zur behandlung von erkrankungen sowie auf die zellmembrane zurueckzufuehrende stoerungen
US5070101A (en) * 1991-02-14 1991-12-03 Mount Sinai School Of Medicine Of The City University Of New York Method and pharmaceutical composition for the treatment of schizophrenia

Also Published As

Publication number Publication date
ZA938835B (en) 1994-08-02
CA2109777A1 (en) 1994-05-27
GB9224809D0 (en) 1993-01-13
DE69305723T2 (de) 1997-04-03
EP0599576A1 (en) 1994-06-01
NZ250265A (en) 1997-06-24
US5516800A (en) 1996-05-14
EP0733360A2 (en) 1996-09-25
EP0599576B1 (en) 1996-10-30
ATE144706T1 (de) 1996-11-15
CN1104494A (zh) 1995-07-05
HK114297A (en) 1997-08-29
GR3021692T3 (en) 1997-02-28
NO934266D0 (no) 1993-11-25
MY109905A (en) 1997-09-30
AU5232996A (en) 1996-07-18
EP0733360A3 (en) 1996-10-02
DK0599576T3 (da) 1996-11-25
AU5183093A (en) 1994-06-09
RU2123844C1 (ru) 1998-12-27
SG47838A1 (en) 1998-04-17
AU666782B2 (en) 1996-02-22
JPH06199663A (ja) 1994-07-19
ES2093935T3 (es) 1997-01-01
DE69305723D1 (de) 1996-12-05

Similar Documents

Publication Publication Date Title
MY109905A (en) Schizophrenia
RU93052390A (ru) Способ лечения шизофрении, применение комбинации арахидоновой и докозагексановой кислот для получения лекарственного средства для лечения шизофрении
NO931923D0 (no) Fettsyre-behandling
AU6247086A (en) Copolymerizable photoinitiators in the nature of acrylic ketones
DK0424028T3 (da) S(+)-ibuprofen-L-aminosyre og S(+)-ibuprofen-D-aminosyre som et forbedret smertestillende middel med fremskyndet indtrædelse
MA19335A1 (fr) Procede d'elimination d'uree d'amoniaque et de bioxydes de carbone de solutions aqueuses diluees.
TW287948B (no)
FR2704543B1 (fr) Procede de traitement d'effluents photographiques par les ultraviolets et le peroxyde d'hydrogene.
FI832592A0 (fi) Foerfarande foer att utfoera elektromikrobiella reduktioner
NO951995D0 (no) Kombinasjon av atovaquon med proguantil for behandling av protozoinfeksjoner
FR2723364B1 (fr) Procede de traitement d'effluents photographiques par les ultraviolets et le peroxyde d'hydrogene
IT1106968B (it) Procedimento per trattare una frazione leggera di rifiuti preferibilmente rifiuti domestici e sistema per l'attuazione del procedimento
ATE45724T1 (de) Okuloselektive betablocker.
DE3671371D1 (de) Kombinationspraeparat.
HU205328B (en) Process for increasing the efficiency and reducing the sludge emission of clarification process used in treatment of water and sewage
SE8802341D0 (sv) Anordning for uppstellning av t ex batar
JPS5676295A (en) Clarification of polluted water
RO83535A2 (ro) Procedeu de prelucrare a namolurilor anodice a zgurilor si prafurilorvolatile stibioase
IT1198645B (it) Macchina fotografica da ripresa industriale del tipo reprocamera per ingrandimenti e riduzioni con lampade regolabili in distanza dall'obbiettivo
IT8120015A0 (it) Trattamento di infezioni virali infiammatorie acne dermatiti e stati di artrite.
NZ336662A (en) Treatment of mania and bipolar disorder with gabapentin
IT8983363A0 (it) Procedimento e dispositivo per energizzare con ioni negativi il potenzionale energetico.